(Q43614006)

25 November 2017

title

The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. (English)

1 reference

25 November 2017

1 reference

Steiner M

1

1 reference

25 November 2017

Romano SJ

2

1 reference

25 November 2017

Babcock S

3

1 reference

25 November 2017

Dillon J

4

1 reference

25 November 2017

Shuler C

5

1 reference

25 November 2017

Berger C

6

1 reference

25 November 2017

Carter D

7

1 reference

25 November 2017

Reid R

8

1 reference

25 November 2017

Stewart D

9

1 reference

25 November 2017

Steinberg S

10

1 reference

25 November 2017

Judge R

11

1 reference

25 November 2017

publication date

1 May 2001

1 reference

BJOG: an International Journal of Obstetrics and Gynaecology

25 November 2017

published in

1 reference

25 November 2017

volume

108

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

462-468

1 reference

Paroxetine as a treatment for premenstrual dysphoric disorder

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Premenstrual syndrome: documentation by a linear analog scale compared with two descriptive scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Fluoxetine in the treatment of premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Progesterone metabolite allopregnanolone in women with premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Morning versus evening bright light treatment of late luteal phase dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Therapeutic effect of sleep deprivation in patients with premenstrual syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

The measurement of premenstrual mood symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Late luteal phase dysphoric disorder in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Fluoxetine in the treatment of premenstrual dysphoria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2001.00120.X

10.1111/J.1471-0528.2001.00120.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference